Inclusion Criteria:  Infection with P.vivax parasitaemia; ≥ 6 months and ˂ 15 years of age; Body weight ≥ 5 Kg; Hb > 7 g/dL presence of axillary temperature >37.5 Celsius or history of fever during the past 48 hours; ability to swallow oral medication; Abscence of severe malnutrition (defined as a child whose growth standard is below -3-Z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm circumference < 110 mm) Abscence of febrile conditions due to disease other than malaria (e.g., measles, acute lower respiratory tract infection, severe diarrhea with dehydration) or the known underlying chronic or severe diseases (e.g., cardiac, renal, hepatic diseases, HIV/AIDS); History of hypersensitivity reactions to or contraindicated for any of the medicine(s) being teste d or used as alternative treatment(s); A negative pregnancy test or non-lactating Ability and willingness to comply with the study protocol for the duration of the study, including 6 months of follow up; Informed consent from the patient/parent/guardian. Informed assent in addition to parental consent of any participant between 7 and 14 years of age; Pregnancy test consent from girls of childbearing age (defined as having had menarche) and their parents or guardians;  Exclusion Criteria:  G6PD- Deficiency (< 4.0 U/g Hb) The subject has severe P. vivax malaria as defined by the World Health Organization (WHO) criteria intolerance of or allergy to one of the medications in the study Pregnant or breastfeeding women Inability to tolerate oral medication Blood tranfusion in the last 3 months (as this may mask the G6PD deficiency) Serious or chronic medical condition (cardiac, renal, hepatic diseases, sickle cell disease, HIV/AIDS) History of malaria in the last 30 days